Frank Schweizer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1771734/publications.pdf

Version: 2024-02-01

96 papers

5,044 citations

32 h-index 69 g-index

101 all docs

101 docs citations

times ranked

101

6281 citing authors

#	Article	IF	CITATIONS
1	Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007–19. JAC-Antimicrobial Resistance, 2022, 4, dlab197.	0.9	10
2	Effects of Lysine N-Îq-Methylation in Ultrashort Tetrabasic Lipopeptides (UTBLPs) on the Potentiation of Rifampicin, Novobiocin, and Niclosamide in Gram-Negative Bacteria. Antibiotics, 2022, 11, 335.	1.5	7
3	Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. Drugs, 2022, 82, 533-557.	4.9	12
4	<i>In Vitro</i> Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019. Microbiology Spectrum, 2022, 10, .	1.2	9
5	The Potential of Novel Lipid Agents for the Treatment of Chemotherapy-Resistant Human Epithelial Ovarian Cancer. Cancers, 2022, 14, 3318.	1.7	1
6	Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs, 2021, 81, 233-256.	4.9	20
7	Synthesis of the Carbohydrate Moiety of Glycoproteins from the Parasite Echinococcus granulosus and Their Antigenicity against Human Sera. Molecules, 2021, 26, 5652.	1.7	1
8	Cytotoxic capacity of a novel glycosylated antitumor ether lipid in chemotherapy-resistant high grade serous ovarian cancer in vitro and in vivo. Translational Oncology, 2021, 14, 101203.	1.7	4
9	A niclosamide–tobramycin hybrid adjuvant potentiates cefiderocol against <i>P. aeruginosa</i> . RSC Medicinal Chemistry, 2021, 12, 1565-1573.	1.7	7
10	Dioctanoyl Ultrashort Tetrabasic \hat{l}^2 -Peptides Sensitize Multidrug-Resistant Gram-Negative Bacteria to Novobiocin and Rifampicin. Frontiers in Microbiology, 2021, 12, 803309.	1.5	4
11	Overcoming \hat{I}^2 -Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127575.	1.0	11
12	Electrochemical characterization of the antibiotic hybrid ciprofloxacin-tobramycin. Electrochemistry Communications, 2020, 119, 106825.	2.3	8
13	A Dimer, but Not Monomer, of Tobramycin Potentiates Ceftolozane against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa and Delays Resistance Development. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	11
14	Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. Drugs, 2020, 80, 285-313.	4.9	60
15	Syntheses of l-Rhamnose-Linked Amino Glycerolipids and Their Cytotoxic Activities against Human Cancer Cells. Molecules, 2020, 25, 566.	1.7	6
16	Dilipid Ultrashort Tetrabasic Peptidomimetics Potentiate Novobiocin and Rifampicin Against Multidrug-Resistant Gram-Negative Bacteria. ACS Infectious Diseases, 2020, 6, 1413-1426.	1.8	25
17	Repurposed Antimicrobial Combination Therapy: Tobramycin-Ciprofloxacin Hybrid Augments Activity of the Anticancer Drug Mitomycin C Against Multidrug-Resistant Gram-Negative Bacteria. Frontiers in Microbiology, 2019, 10, 1556.	1.5	34
18	Development of a nebramine-cyclam conjugate as an antibacterial adjuvant to potentiate \hat{l}^2 -lactam antibiotics against multidrug-resistant P. aeruginosa. Journal of Antibiotics, 2019, 72, 816-826.	1.0	15

#	Article	IF	Citations
19	42936 pathogens from Canadian hospitals: 10 years of results (2007–16) from the CANWARD surveillance study. Journal of Antimicrobial Chemotherapy, 2019, 74, iv5-iv21.	1.3	43
20	Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria. Journal of Medicinal Chemistry, 2019, 62, 9103-9115.	2.9	24
21	The Anthelmintic Drug Niclosamide Synergizes with Colistin and Reverses Colistin Resistance in Gram-Negative Bacilli. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	49
22	Potentiation of β-lactam antibiotics and β-lactam/β-lactamase inhibitor combinations against MDR and XDR Pseudomonas aeruginosa using non-ribosomal tobramycin–cyclam conjugates. Journal of Antimicrobial Chemotherapy, 2019, 74, 2640-2648.	1.3	30
23	Amphiphilic nebramine-based hybrids Rescue legacy antibiotics from intrinsic resistance in multidrug-resistant Gram-negative bacilli. European Journal of Medicinal Chemistry, 2019, 175, 187-200.	2.6	19
24	Heterodimeric Rifampicin–Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol inÂvitro and in a Galleria mellonella inÂvivo model. European Journal of Medicinal Chemistry, 2019, 174, 16-32.	2.6	27
25	Synergistic combinations of anthelmintic salicylanilides oxyclozanide, rafoxanide, and closantel with colistin eradicates multidrug-resistant colistin-resistant Gram-negative bacilli. Journal of Antibiotics, 2019, 72, 605-616.	1.0	28
26	Polybasic peptide–levofloxacin conjugates potentiate fluoroquinolones and other classes of antibiotics against multidrug-resistant Gram-negative bacteria. MedChemComm, 2019, 10, 517-527.	3.5	16
27	Synthesis of the Non Reducing End Oligosaccharides of Glycosphingolipids from <i>Ascaris suum</i> . Chemical and Pharmaceutical Bulletin, 2019, 67, 143-154.	0.6	4
28	Enhancing uptake of antibiotics into Gram-negative bacteria using nonribosome-targeting aminoglycoside-based adjuvants. Future Medicinal Chemistry, 2019, 11, 1519-1522.	1.1	7
29	Dilipid ultrashort cationic lipopeptides as adjuvants for chloramphenicol and other conventional antibiotics against Gram-negative bacteria. Amino Acids, 2019, 51, 383-393.	1.2	19
30	Amphiphilic lysine conjugated to tobramycin synergizes legacy antibiotics against wildâ€type and multidrugâ€resistant <i>Pseudomonas aeruginosa</i> . Peptide Science, 2019, 111, e23091.	1.0	18
31	Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs, 2019, 79, 271-289.	4.9	274
32	Short Proline-Rich Lipopeptide Potentiates Minocycline and Rifampin against Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2018, 62,	1.4	28
33	Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?. Clinical Microbiology Reviews, 2018, 31, .	5 . 7	218
34	Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Drugs, 2018, 78, 65-98.	4.9	291
35	Development of dilipid polymyxins: Investigation on the effect of hydrophobicity through its fatty acyl component. Bioorganic Chemistry, 2018, 80, 639-648.	2.0	16
36	Tobramycin-Linked Efflux Pump Inhibitor Conjugates Synergize Fluoroquinolones, Rifampicin and Fosfomycin against Multidrug-Resistant Pseudomonas aeruginosa. Journal of Clinical Medicine, 2018, 7, 158.	1.0	23

3

#	Article	IF	CITATIONS
37	Absolute Quantitation of Glycoforms of Two Human IgG Subclasses Using Synthetic Fc Peptides and Glycopeptides. Journal of the American Society for Mass Spectrometry, 2018, 29, 1086-1098.	1.2	13
38	Replacing <scp>d</scp> -Glucosamine with Its <scp>l</scp> -Enantiomer in Glycosylated Antitumor Ether Lipids (GAELs) Retains Cytotoxic Effects against Epithelial Cancer Cells and Cancer Stem Cells. Journal of Medicinal Chemistry, 2017, 60, 2142-2147.	2.9	13
39	Amphiphilic Tobramycin–Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. Journal of Medicinal Chemistry, 2017, 60, 3684-3702.	2.9	71
40	A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. Journal of Medicinal Chemistry, 2017, 60, 3913-3932.	2.9	57
41	Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells. Journal of Experimental and Clinical Cancer Research, 2017, 36, 67.	3.5	6
42	Amphiphilic Modulation of Glycosylated Antitumor Ether Lipids Results in a Potent Triamino Scaffold against Epithelial Cancer Cell Lines and BT474 Cancer Stem Cells. Journal of Medicinal Chemistry, 2017, 60, 9724-9738.	2.9	20
43	Polymyxin B3–Tobramycin Hybrids with Pseudomonas aeruginosa-Selective Antibacterial Activity and Strong Potentiation of Rifampicin, Minocycline, and Vancomycin. ACS Infectious Diseases, 2017, 3, 941-954.	1.8	26
44	Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities. Antibiotics, 2017, 6, 26.	1.5	66
45	Adjuvants Based on Hybrid Antibiotics Overcome Resistance in <i>Pseudomonas aeruginosa</i> and Enhance Fluoroquinolone Efficacy. Angewandte Chemie - International Edition, 2016, 55, 555-559.	7.2	80
46	Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs, 2016, 76, 1737-1757.	4.9	38
47	Multiplexed azidoâ€group isotopic capture (MAGIC) beads: Selective analysis of azido compounds using a propargylâ€based cleavable linker, a proof of concept. Rapid Communications in Mass Spectrometry, 2016, 30, 2497-2507.	0.7	0
48	Ultrashort cationic lipopeptides and lipopeptoids: Evaluation and mechanistic insights against epithelial cancer cells. Peptides, 2016, 84, 58-67.	1.2	30
49	Design, synthesis and evaluation of cytotoxic properties of bisamino glucosylated antitumor ether lipids against cancer cells and cancer stem cells. MedChemComm, 2016, 7, 2100-2110.	3.5	10
50	Hybrid Antibiotic Overcomes Resistance in <i>P. aeruginosa</i> by Enhancing Outer Membrane Penetration and Reducing Efflux. Journal of Medicinal Chemistry, 2016, 59, 8441-8455.	2.9	70
51	Synthesis and Antigenicity against Human Sera of a Biotin-Labeled Oligosaccharide Portion of a Glycosphingolipid from the Parasite <i>Echinococcus multilocularis</i> . Chemical and Pharmaceutical Bulletin, 2016, 64, 865-873.	0.6	5
52	Structural modifications of the neomycin class of aminoglycosides. MedChemComm, 2016, 7, 1499-1534.	3.5	14
53	Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. Drugs, 2016, 76, 567-588.	4.9	199
54	Cancer stem cells, cancer-initiating cells and methods for their detection. Drug Discovery Today, 2016, 21, 836-842.	3.2	66

#	Article	IF	CITATIONS
55	Design, synthesis and antitumor properties of glycosylated antitumor ether lipid (GAEL)-chlorambucil-hybrids. Chemistry and Physics of Lipids, 2016, 194, 139-148.	1.5	16
56	Short Antimicrobial Peptides and Peptide Scaffolds as Promising Antibacterial Agents. Current Topics in Medicinal Chemistry, 2016, 16, 1217-1230.	1.0	45
57	Amphiphilic Tobramycins with Immunomodulatory Properties. Angewandte Chemie - International Edition, 2015, 54, 6278-6282.	7.2	50
58	Synthetic Glycosylated Ether Glycerolipids as Anticancer Agents. RSC Drug Discovery Series, 2015, , 151-179.	0.2	2
59	Structure–activity relationships in ultrashort cationic lipopeptides: the effects of amino acid ring constraint on antibacterial activity. Amino Acids, 2014, 46, 2517-2530.	1.2	22
60	Ceftolozane/Tazobactam: A Novel Cephalosporin/ \hat{l}^2 -Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli. Drugs, 2014, 74, 31-51.	4.9	279
61	Cytotoxic properties of d-gluco-, d-galacto- and d-manno-configured 2-amino-2-deoxy-glycerolipids against epithelial cancer cell lines and BT-474 breast cancer stem cells. European Journal of Medicinal Chemistry, 2014, 78, 225-235.	2.6	20
62	Structure–Activity Relationships of Glucosamineâ€Derived Glycerolipids: the Role of the Anomeric Linkage, the Cationic Charge and the Glycero Moiety on the Antitumor Activity. ChemMedChem, 2013, 8, 511-520.	1.6	15
63	Ceftazidime-Avibactam: a Novel Cephalosporin/ \hat{l}^2 -lactamase Inhibitor Combination. Drugs, 2013, 73, 159-177.	4.9	362
64	Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. Journal of Antimicrobial Chemotherapy, 2013, 68, i7-i22.	1.3	114
65	Structure Activity Relationships of N-linked and Diglycosylated Glucosamine-Based Antitumor Glycerolipids. Molecules, 2013, 18, 15288-15304.	1.7	9
66	Ultrashort Cationic Lipopeptides and Lipopeptoids Selectively Induce Cytokine Production in Macrophages. PLoS ONE, 2013, 8, e54280.	1.1	13
67	Antibacterial activity of amphiphilic tobramycin. Journal of Antibiotics, 2012, 65, 495-498.	1.0	40
68	Synthetic studies on glycosphingolipids from protostomia phyla: synthesis of glycosphingolipids and related carbohydrate moieties from the parasite Schistosoma mansoni. Carbohydrate Research, 2012, 361, 55-72.	1.1	12
69	Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Review of Anti-Infective Therapy, 2012, 10, 459-473.	2.0	171
70	Investigating the antimicrobial peptide â€~window of activity' using cationic lipopeptides with hydrocarbon and fluorinated tails. International Journal of Antimicrobial Agents, 2012, 40, 36-42.	1.1	31
71	Synthesis and Antibacterial Activities of Amphiphilic Neomycin B-based Bilipid Conjugates and Fluorinated Neomycin B-based Lipids. Molecules, 2012, 17, 9129-9141.	1.7	25
72	Synthesis, Antigenicity Against Human Sera and Structure-Activity Relationships of Carbohydrate Moieties from Toxocara larvae and Their Analogues. Molecules, 2012, 17, 9023-9042.	1.7	11

#	Article	IF	Citations
73	Guanidylation and Tail Effects in Cationic Antimicrobial Lipopeptoids. PLoS ONE, 2012, 7, e41141.	1.1	26
74	Synthesis, Inhibitory Effects on Nitric Oxide and Structure-Activity Relationships of a Glycosphingolipid from the Marine Sponge Aplysinella rhax and Its Analogues. Molecules, 2011, 16, 637-651.	1.7	6
75	Synthesis and antibacterial activity of amphiphilic lysine-ligated neomycin B conjugates. Carbohydrate Research, 2011, 346, 560-568.	1.1	37
76	Synthesis of the carbohydrate moiety from the parasite Echinococcus multilocularis and their antigenicity against human sera. European Journal of Medicinal Chemistry, 2011, 46, 1768-1778.	2.6	22
77	Synthetic Studies on Glycosphingolipids from Protostomia Phyla: Synthesis of Glycosphingolipids from the Parasite Schistosoma mansoni. Chemical and Pharmaceutical Bulletin, 2010, 58, 811-817.	0.6	9
78	Evaluation of amphiphilic aminoglycoside–peptide triazole conjugates as antibacterial agents. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3031-3035.	1.0	53
79	Antibacterial activity of guanidinylated neomycin B- and kanamycin A-derived amphiphilic lipid conjugates. Journal of Antimicrobial Chemotherapy, 2010, 65, 1224-1227.	1.3	55
80	Prevalence of Antimicrobial-Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrobial Agents and Chemotherapy, 2010, 54, 4684-4693.	1.4	138
81	Antibacterial Activities of Aminoglycoside Antibiotics-Derived Cationic Amphiphiles. Polyol-Modified Neomycin B-, Kanamycin A-, Amikacin-, and Neamine-Based Amphiphiles with Potent Broad Spectrum Antibacterial Activity. Journal of Medicinal Chemistry, 2010, 53, 3626-3631.	2.9	76
82	Contiguous <i>$>$O</i> $>$ -Galactosylation of 4(<i>$>$R</i> $>$)-Hydroxy- <scp> </scp> -proline Residues Forms Very Stable Polyproline II Helices. Journal of the American Chemical Society, 2010, 132, 5036-5042.	6.6	49
83	Cationic Amphiphiles, a New Generation of Antimicrobials Inspired by the Natural Antimicrobial Peptide Scaffold. Antimicrobial Agents and Chemotherapy, 2010, 54, 4049-4058.	1.4	256
84	Prevalence of Antimicrobial-Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2007). Canadian Journal of Infectious Diseases and Medical Microbiology, 2009, 20, 9A-19A.	0.7	14
85	Antibacterial Activity of Ultrashort Cationic Lipo-Î ² -Peptides. Antimicrobial Agents and Chemotherapy, 2009, 53, 2215-2217.	1.4	46
86	Cationic amphiphilic peptides with cancer-selective toxicity. European Journal of Pharmacology, 2009, 625, 190-194.	1.7	424
87	Synthetic studies on the carbohydrate moiety of the antigen from the parasite Echinococcusmultilocularis. Carbohydrate Research, 2009, 344, 856-868.	1.1	25
88	Carbohydrate Chemistry and Biochemistry. Von Michaelâ€L. Sinnott Angewandte Chemie, 2008, 120, 5780-5781.	1.6	0
89	Synthesis of glucose-templated lysine analogs and incorporation into the antimicrobial dipeptide sequence kW-OBn. Carbohydrate Research, 2008, 343, 1644-1652.	1.1	11
90	Design, Synthesis, and Antibacterial Activities of Neomycinâ [^] 'Lipid Conjugates: Polycationic Lipids with Potent Gram-Positive Activity. Journal of Medicinal Chemistry, 2008, 51, 6160-6164.	2.9	96

#	Article	IF	CITATIONS
91	Synthesis of fluorescently labelled and internally quenched UDP-Gal probes. Carbohydrate Research, 2007, 342, 1831-1840.	1.1	5
92	Synthesis of a galacto-configured C-ketoside-based \hat{I}^3 -sugar-amino acid and its use in peptide coupling reactions. Carbohydrate Research, 2006, 341, 1730-1736.	1.1	23
93	Synthesis of Internally Fluorescence-Quenched Sugar Nucleotides. Synlett, 2004, 2004, 1784-1788.	1.0	7
94	Glycosamino Acids: Building Blocks for Combinatorial Synthesisâ€"Implications for Drug Discovery. Angewandte Chemie - International Edition, 2002, 41, 230.	7.2	211
95	Synthesis of a 56 Component Library of Sugar & Deptides. Combinatorial Chemistry and High Throughput Screening, 2002, 5, 389-394.	0.6	11
96	Synthesis of Sugar-fused GABA-analogs. Synlett, 2001, 2001, 1743-1746.	1.0	19